Abstract:Abstract Background Porcine circovirus type 2 (PCV2) is the causative agent of postweaning multisystemic wasting syndrome, and is associated with a number of other diseases. PCV2 is widely distributed in most developed swine industries, and is a severe economic burden. With an eye to developing an effective, safe, and convenient vaccine against PCV2-associated diseases, we have constructed a recombinant Bacillus subtilis strain ( B. subtilis -Cap) that expresses the PCV2 capsid protein (Cap). Methods Electroporation of a plasmid shuttle vector encoding the PCV2 Cap sequence was use to transform Bacillus subtilis . Flow cytometry was used to evaluate in vitro bone marrow derived dendritic cell (BM-DC) maturation and T cell proliferation induced by B. subtilis -Cap. Orally inoculated piglets were used for in vivo experiments; ELISA and western blotting were used to evaluate B. subtilis -Cap induced PCV2-specific IgA and IgG levels, as well as the secretion of cytokines and the expression of Toll-like receptor 2 (TLR2) and Toll-like receptor 9 (TLR9). Results We evaluated the immune response to B. subtilis -Cap in vitro using mouse BM-DCs and in vivo using neonatal piglets orally inoculated with B. subtilis -Cap. Our results showed that the recombinant B. subtilis -Cap activated BM-DCs, significantly increased co-stimulatory molecules (CD40 and CD80) and major histocompatibility complex II, and induced allogenic T cells proliferation. Piglets immunized with B. subtilis -Cap had elevated levels of PCV2-specific IgA in the mucosal tissues of the digestive and respiratory tract, and PCV2-specific IgG in serum ( P < 0.05 or P < 0.01). Ileal immunocompetent cells, such as the IgA-secreting cells ( P < 0.01), intestinal intraepithelial lymphocytes (IELs) ( P < 0.01), CD3 + T lymphocytes ( P < 0.01) and CD4 + T lymphocytes ( P < 0.01) increased significantly in the B. subtilis -Cap immunized piglets. Additionally, B. subtilis -Cap inoculation resulted in increased the expression of TLR2 and TLR9 ( P < 0.01), and induced the secretion of cytokines IL-1β, IL-6, interferon-γ, and β-defensin 2 ( P < 0.01). Conclusions We constructed a prototype PCV2 vaccine that can be administered orally and elicits a more robust humoral and cellular immunity than inactivated PCV2. B. subtilis -Cap is a promising vaccine candidate that is safe, convenient, and inexpensive. Further in vivo research is needed to determine its full range of efficacy in pigs. Graphical abstract

Immunogenicity of recombinant classic swine fever virus CD8(+) T lymphocyte epitope and porcine parvovirus VP2 antigen coexpressed by Lactobacillus casei in swine via oral vaccination.

Co-expression of CSFV T Cell Epitope E290 Peptide and PPV VP2 Protein in Lactobacillus Casei and Determination of Specific Antibodies in Immunized Mice

Immunogenicity in Swine of Orally Administered Recombinant Lactobacillus Plantarum Expressing Classical Swine Fever Virus E2 Protein in Conjunction with Thymosin Α-1 As an Adjuvant

Construction of Recombinant Lactobacillus Casei Efficiently Surface Displayed and Secreted Porcine Parvovirus VP2 Protein and Comparison of the Immune Responses Induced by Oral Immunization

Expression of Porcine parvovirus-like Particles Carrying a CSFV T Cell Epitope and Its Immunization on Mice

Induction of immune responses in mice after intragastric administration of Lactobacillus casei producing porcine parvovirus VP2 protein.

Recombinant porcine rotavirus VP4 and VP4-LTB expressed in Lactobacillus casei induced mucosal and systemic antibody responses in mice

Construction of Lactobacillus casei Expressing Recombinant Classical Swine Fever Virus T Cell Epitope and Porcine Parvovirus VP2 Protein

Immune Responses in Pigs Induced by Recombinant DNA Vaccine Co-Expressing Swine IL-18 and Membrane Protein of Porcine Reproductive and Respiratory Syndrome Virus.

Construction and immunogenicity of recombinant porcine circovirus-like particles displaying somatostatin.

Immune response in piglets orally immunized with recombinant Bacillus subtilis expressing the capsid protein of porcine circovirus type 2

Analysis of Immune Responses Induced by Recombinant Secretion and Non-secretion Type Lactobacillus Casei Expressing Porcine Parvovirus VP2 Protein Via Oral Immunizations

The Immune Response Induced in Mice Orally Immunized with Lactobacillus Casei Expressing Porcine Parvovirus VP2 Protein

A Genetically Engineered Bivalent Vaccine Coexpressing a Molecular Adjuvant against Classical Swine Fever and Porcine Epidemic Diarrhea

Strategy of Developing Oral Vaccine Candidates Against Co-infection of Porcine Diarrhea Viruses Based on a Lactobacillus Delivery System

Immune responses in pigs induced by recombinant canine adenovirus 2 expressing the glycoprotein 5 of porcine reproductive and respiratory syndrome virus

Development of a Combined Genetic Engineering Vaccine for Porcine Circovirus Type 2 and Mycoplasma Hyopneumoniae by a Baculovirus Expression System

A Subunit Vaccine Based on the VP2 Protein of Porcine Parvovirus 1 Induces a Strong Protective Effect in Pregnant Gilts

Efficient Mucosal Vaccination of a Novel Classical Swine Fever Virus E2-Fc Fusion Protein Mediated by Neonatal Fc Receptor.

Surface Display of porcine circovirus type 2 antigen protein cap on the spores of bacillus subtilis 168: An effective mucosal vaccine candidate

Surface Display of Antigen Protein VP8* of Porcine Rotavirus on Bacillus Subtilis Spores Using CotB as a Fusion Partner